Mitozolomide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mitozolomide
Mitozolomide.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
ECHA InfoCard 100.079.921
Chemical and physical data
Formula C7H7ClN6O2
Molar mass 242.622 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]

References[edit]

  1. ^ Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA (February 2000). "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide" (PDF). Cancer Gene Ther. 7 (2): 233–9. doi:10.1038/sj.cgt.7700120. PMID 10770631. 
  2. ^ Newlands ES, Blackledge GR, Slack JA, et al. (February 1992). "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)". Br J Cancer. 65 (2): 287–91. doi:10.1038/bjc.1992.57. PMC 1977719Freely accessible. PMID 1739631.